Autophagy targets in neurodegeneration
We are excited to announce a new collaboration which has been set up through the Milner Therapeutics Consortium to investigate autophagy targets in neurodegeneration. This is the first such project to bring together multiple academic groups across the University and...
Milner Consortium reaches 10
We are excited to announce that two new pharma partners — Eli Lilly and Company and Bristol Myers Squibb — have joined the Milner Consortium in the past month. Now with ten pharma partners and three academic partners, this has become one of the largest cross-sector...
Start Codon closes new £15 million venture fund
Start Codon, the life science and healthcare business accelerator based in the Milner Therapeutics Institute, today announced that it has closed Start Codon Fund I LP (the “Fund”) at £15 million. The Fund will be used to support Start Codon’s offering to start-ups,...
OncoInnovation: TGIO 2020 Challenge winner
Last month, the Translating Genomics in Oncology (TGIO) 2020 event was co-organized by two programmes of the CRUK Cambridge Centre – Early Detection and OncoInnovation – together with the University Enterprise Zone. The OncoInnovation programme is delivered in the...